Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 15, Number 7—July 2009

Letter

Acanthamoeba spp. in Urine of Critically Ill Patients

Suggested citation for this article

To the Editor: Free-living amebae are ubiquitous protists able to endure extreme temperature and pH in diverse environments (1). In past decades, interest in them increased as causes of infections, such as keratitis (2) and granulomatous encephalitis (3). Acanthamoeba spp. can harbor pathogenic microorganisms as endosymbionts, such as bacteria (e.g., Legionella spp., Pseudomonas aeruginosa, and Vibrio cholera), fungi, and mycobacteria (4).

The occasional observation of amebae in urine specimens in a clinical microbiology laboratory (by L.C.S.) motivated our study. To estimate the prevalence of Acanthamoeba spp. in urine, on March 3 and 4, 2008, we collected urine samples from indwelling urinary catheters of all critically ill patients in the intensive care units of a tertiary care 2,000-bed university hospital (Hospital das Clínicas, University of São Paulo). Medical records were evaluated for patient age, sex, underlying diseases, length of hospital stay, use of central venous catheter, mechanical ventilation, antimicrobial drug use, and duration of urinary catheterization.

Chemical urinalysis was performed by using a urine dipstick (Uriquest; Labtest Diagnostica, Lagoa Santa, Minas Gerais, Brazil), and urine leukocyte and erythrocyte counts were performed. Samples were examined microscopically and cultured for amebae. Amebae were characterized on the basis of morphologic criteria (cyst morphology and trophozoite shape and motility) (5). For ameba culture, 10 mL of urine was centrifuged at 2,500 rpm for 5 min. The supernatant was discarded, and the sediment (1 mL) was added to 5 mL of brain-heart infusion (Oxoid, Cambridge, UK). Cultures were incubated at 25oC for 48 hr and microscopically examined. For this study, finding trophozoites on direct examination or growing Acanthamoeba on culture were considered a positive result for the patient.

Pipet tips (10), vacuum containers (10), plastic 15-mL tubes (10), syringes (10), glass slides (20), and tubes containing medium (10) were submitted for direct examination and culture for ameba to ensure that they were not contaminated. Urine samples were cultured for bacteria and fungi. Urine samples were submitted for bacterial and fungal direct examinations, and cultures were performed (6). If found, organisms were identified by morphologic, biochemical, and Gram stain characteristics.

Data from patients with and without Acanthamoeba spp. were compared. For dichotomous variables, we used χ2 to calculate odds ratios and 95% confidence intervals. For continuous variables, the Mann-Whitney test was used. Results were significant at p<0.05.

A total of 63 urine samples were evaluated; 17 (26%) were positive for Acanthamoeba spp. (Table). All samples of the control materials and medium tested showed negative results.

The high prevalence of Acanthamoeba spp. in the urine of critically ill patients is difficult to explain. Although Acanthamoeba spp. can cause severe infections, amebae also carry pathogenic microorganisms (4). Bacteria may serve as food for amebae, but other interactions exist; for example, bacteria take advantage of the protection offered by amebae, especially in the cystic form (4). P. aeruginosa, Escherichia coli, and Proteus mirabilis can infect free-living amebae (7). The presence of Acanthamoeba spp. in critically ill patients may be advantageous to potentially pathogenic bacteria in the urine, protecting them against antimicrobial drugs, disinfectants, and host immunity. In this sense Acanthamoeba spp. may be a reservoir for pathogenic bacterial agents in severely ill patients or, as Khan described, a “Trojan horse for bacteria” (1). However, we found no association between the presence of Acanthamoeba spp. of bacteria and fungi in the urine.

Biofilms are attractive niches for Acanthamoeba spp. that may provide nutritional requirements and protection against disinfectants and antimicrobial drugs (1). After 7 days in a patient, most urinary catheters contain a biofilm (8). However, we found no association between duration of catheterization and presence of Acanthamoeba spp. Also, P. aeruginosa isolates from clinical infections have shown more virulence toward Acanthamoeba spp. than environmental samples (9).

Another possible explanation is the direct pathogenic activity of Acanthamoeba spp. In a study to determine whether ameba-associated microorganisms are a cause of nosocomial pneumonia, in 5 of 210 cases, Acanthamoeba sp. was considered the only cause of infection (10). In our study, patients positive for Acanthamoeba spp. had a higher mean and median of urine leukocytes and erythrocytes, suggesting aggression by the amebae. On the other hand, even these higher counts among positive patients are considered relatively low. Cardiovascular disease, cancer, and diabetes were associated with carriage of Acanthamoeba spp., which may occur in more severely ill patients. As a final possibility, Acanthamoeba spp. in the urine could have no role at all and may even reflect contamination during catheterization.

This study has limitations. It was a small, preliminary investigation designed only to evaluate the presence of Acanthamoeba spp. in urine. However, our findings should lead to further studies to increase knowledge about the role of free-living amebae in nosocomial infections.

Univariate analysis of variables potentially associated with <italic>Acanthamoeba</italic> spp. in urine samples from critically ill patients, Hospital das Clínicas, University of São Paulo, Brazil, March 2008*
Variable Sample positive for Acanthamoeba spp.† Sample negative for Acanthamoeba spp.‡ OR 95% CI p value
No. (%) patients
Male sex 10 (59) 28 (61) 0.92 0.30–2.95 0.88
Antimicrobial drug use 13 (77) 35 (76) 1.02 0.28–3.78 0.97
Use of mechanical ventilation 10 (59) 23 (70) 1.43 0.46–4.40 0.53
Presence of central venous catheter 12 (75)§ 33 (72) 1.18 0.32–4.34 0.80
Urine culture positive for bacteria/fungi
Any count 9 (53) 21 (46) 1.34 0.44–4.09 0.61
>105 CFU/mL 8 (47) 13 (28) 2.26 0.72–7.12 0.16
Underlying diseases
Cardiovascular 15 (88) 26 (57) 5.77 1.06–41.34 0.02
Infectious diseases 10 (59) 21 (46) 1.70 0.48–6.09 0.35
Cancer 9 (53) 9 (20) 4.63 1.20–18.40 0.01
Diabetes mellitus 5 (29) 3 (7) 5.97 1.02–38.03 0.02
Renal Insufficiency 2 (12) 6 (13) 0.89 0.11–5.81 0.89
Acute abdomen 2 (12) 4 (9) 1.40 0.16–10.44 0.71
Trauma 1 (6) 11 (24) 0.20 0.01–1.74 0.11
Respiratory 1 (6) 5 (11) 0.51 0.02–5.24 0.55
Neurologic 1 (6) 4 (9) 0.66 0.03–7.19 0.71
Others
8 (47)
19 (35)
1.26
0.36–4.45
0.68
Age, y
Mean (SD) 62.4 (13.9) 54.7 (16.2) 0.05
Median (range)
64.6 (20.5–77.5)
53.4 (17.7–80.8)



Length of hospital stay, d
Mean (SD) 16.3 (12.8) 13.5 (11.3) 0.45
Median (range)
11 (2–43)
9 (1–48)



Length of ICU stay, d
Mean (SD) 6.9 (9.0) 9.4 (10.4) 0.18
Median (range)
3.0 (1–31)
5.5 (0–47)



Duration of urinary catheterization, d
Mean (SD) 8.3 (9.8) 10.4 (9.4) 0.17
Median (range)
4.0 (1–33)
8.5 (1–33)



Leukocyte count in urine per high-power field
Mean (SD) 10.9 (17.4) 3.59 (10.53) 0.009
Median (range)
3.5 (0–60)
1.0 (0–70)



Erythrocyte count in urine per high-power field
Mean (SD) 35.8 (42.6) 17.7 (27.9) 0.03
Median (range)
18.5 (0–150)
4.0 (0–120)



Urine pH
Mean (SD) 5.4 (0.8) 5.8 (1.1) 0.18
Median (range) 5 (5–8) 5 (5–8.5)

*OR, odds ratio; CI, confidence interval.
†n = 17 except as indicated.
‡n = 46.
§n = 16.

Leonilda C. Santos, Maura S. Oliveira, Renata D. Lobo, Hermes R. Higashino, Silvia F. Costa, Inneke M. van der Heijden, Mauro C. Giudice, Atalanta R. Silva, and Anna S. LevinComments to Author 
Author affiliations: Itaipu Binacional and Universidade do Oeste do Paraná, Paraná, Brazil (L.C. Santos); University of São Paulo, São Paulo, Brazil (M.S. Oliveira, R.D. Lobo, H.R. Higashino, S.F. Costa, I.M. van der Heijden, M.C. Giudice, A.R. Silva, A.S. Levin)

Acknowledgment

We thank M.P. Freire, T. Guimarães, C.A. Silva, P.B. Martino, C.R. Santos, G.V.B. Prado, S.F. Raymundo, C.P. Garcia, F.G. Nascimento, and R. Vasconcelos for their participation during the collection phase of the study. We also thank Annette Foronda for her comments on methods.

References

  1. Khan NA. Acanthamoeba: biology and increasing importance in human health. FEMS Microbiol Rev. 2006;30:56495. DOIPubMed
  2. Thebpatiphat N, Hammersmith KM, Rocha FN, Rapuano CJ, Ayres BD, Laibson PR, Acanthamoeba keratitis: a parasite on the rise. Cornea. 2007;26:7016. DOIPubMed
  3. Khan NA. Acanthamoeba invasion of the central nervous system. Int J Parasitol. 2007;37:1318. DOIPubMed
  4. Winiecka-Krusnell J, Linder E. Bacterial infections of free-living amoebae. Res Microbiol. 2001;152:6139. DOIPubMed
  5. Oddó BD. Infections caused by free-living amebas. Historical commentaries, taxonomy and nomenclature, protozoology and clinicopathologic features [in Spanish]. Rev Chilena Infectol. 2006;23:20014.PubMed
  6. Oplustil CP, Zoccoli CM, Tobouti NR, Sinto SI. Procedimentos básicos em microbiologia clínica. 2nd ed. São Paulo (Brazil): Sarvier; 2004.
  7. Walochnik J, Oicher O, Aspöck C, Ullmann M, Sommer R, Aspöck H. Interactions of “Limax amoebae” and gram-negative bacteria: experimental studies and review of current problems. Tokai J Exp Clin Med. 1998;23:2738.PubMed
  8. Morris NS, Stickler DJ, McLean RJC. The development of bacterial biofilms on indwelling urethral catheters. World J Urol. 1999;17:34550. DOIPubMed
  9. Fenner L, Richet H, Raoult D, Papazian L, Martin C, La Scola B. Are clinical isolates of Pseudomonas aeruginosa more virulent than hospital environmental isolates in amebal co-culture test? Crit Care Med. 2006;34:8238. DOIPubMed
  10. Berger P, Papazian L, Drancourt M, La Scola B, Auffray JP, Raoult D. Amoeba-associated microorganisms and diagnosis of nosocomial pneumonia. Emerg Infect Dis. 2006;12:24855.PubMed

Suggested citation for this article: Santos LC, Oliveira MS, Lobo RD, Higashino HR, Costa SF, van der Heijden IM, et al. Acanthamoeba spp. in urine of critically ill patients [letter]. Emerg Infect Dis [serial on the Internet]. 2009 Jul [date cited]. Available from http://wwwnc.cdc.gov/eid/article/15/7/08-1415

DOI: 10.3201/eid1507.081415

Related Links

Table of Contents – Volume 15, Number 7—July 2009

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Anna S. Levin, Rua Banibas, 618, São Paulo-SP 05460-010, Brazil;


character(s) remaining.

Comment submitted successfully, thank you for your feedback.

TOP